TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual MeetingGlobeNewsWire • 04/16/21
TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple SclerosisGlobeNewsWire • 04/15/21
TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic LeukemiaGlobeNewsWire • 03/29/21
Strength Seen in TG Therapeutics (TGTX): Can Its 6.7% Jump Turn into More Strength?Zacks Investment Research • 03/22/21
TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma in the Journal of Clinical OncologyGlobeNewsWire • 03/09/21
TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual MeetingGlobeNewsWire • 03/04/21
TG Therapeutics' (TGTX) CEO Michael Weiss on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/02/21
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business UpdateGlobeNewsWire • 02/26/21
TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet HaematologyGlobeNewsWire • 02/23/21
TG Therapeutics to Participate in the B. Riley Securities Oncology Investor ConferenceGlobeNewsWire • 01/15/21
TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/08/21
Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock?Zacks Investment Research • 12/24/20
TG Therapeutics Stock Jumps On Positive Results For Multiple Sclerosis TreatmentInvestors Business Daily • 12/10/20
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple SclerosisGlobeNewsWire • 12/10/20
TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual MeetingGlobeNewsWire • 12/07/20